Pre- versus postmenopausal age, estradiol, and peptide-secretagogue type determine pulsatile growth hormone secretion in healthy women: studies using submaximal agonist drive and an estrogen clamp.

Hudson SB, Schroeder DR, Bailey JN, Mielke KL, Erickson D, Miles JM, Bowers CY, Veldhuis JD

The Journal of clinical endocrinology and metabolism26 Oct 2009Cited by 11 (Europe PMC)

PMID19858315PMCIDPMC2805499DOI10.1210/jc.2009-1769PepBankPUB-19858315

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

1 result from studies that gave the peptide. 1 result from people.

01HumanRandomized controlled trialEfficacy outcome
In healthy pre- and postmenopausal women, a half-maximal GHRP‑2 bolus stimulated more pulsatile GH secretion than a GHRH bolus of the same dose.
In plain wordsIn healthy women, GHRP‑2 raised pulsatile growth hormone release more than GHRH at the same dose.
Peptide
GHRP-2
Outcome
IncreaseSubmaximally stimulated pulsatile GH secretion, GHRP-2 vs GHRH
Study
n = 42
Comparator
GHRH
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.33 mug/kg · iv bolusAs given in this study (human).
Source sentences
Summary
Submaximally stimulated pulsatile GH secretion was positively determined by PRE vs. POST age (P < 0.001), E(2) repletion vs. depletion (P = 0.001) and GHRP-2 vs. GHRH stimulation (P < 0.001), after adjustment for AVF and basal secretion.
2 context sentences(design, population, supporting numbers)
Summary · context
Community-dwelling healthy premenopausal (PRE, age 24 +/- 0.8 yr, n = 20) and postmenopausal (POST, age 63 +/- 1.8 yr, n = 22) women participated in the study.
Summary · context
Gonadal-axis down-regulation with leuprolide was followed by randomized addback of placebo or transdermal E(2) and separate-day iv bolus injections of a half-maximally stimulatory dose of GHRP-2 or GHRH (each 0.33 mug/kg).
Report a problemFND-1985831501

Studies that did not test the peptide alone4

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

02HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome
In healthy women given GHRP‑2 or GHRH, pulsatile GH secretion was higher in premenopausal than in postmenopausal women, after adjustment for AVF and basal secretion.
In plain wordsIn healthy women given GHRP‑2 or GHRH, younger premenopausal women released more pulsatile growth hormone than postmenopausal women.
Peptide
GHRP-2
Outcome
Not applicablePulsatile GH secretion, premenopausal vs postmenopausal age
Study
n = 42
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
Submaximally stimulated pulsatile GH secretion was positively determined by PRE vs. POST age (P < 0.001), E(2) repletion vs. depletion (P = 0.001) and GHRP-2 vs. GHRH stimulation (P < 0.001), after adjustment for AVF and basal secretion.
2 context sentences(design, population, supporting numbers)
Summary · context
Community-dwelling healthy premenopausal (PRE, age 24 +/- 0.8 yr, n = 20) and postmenopausal (POST, age 63 +/- 1.8 yr, n = 22) women participated in the study.
Summary · context
Gonadal-axis down-regulation with leuprolide was followed by randomized addback of placebo or transdermal E(2) and separate-day iv bolus injections of a half-maximally stimulatory dose of GHRP-2 or GHRH (each 0.33 mug/kg).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1985831502
03HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome
In healthy women given GHRP‑2 or GHRH, E2 repletion increased pulsatile GH secretion versus depletion.
In plain wordsIn healthy women given GHRP‑2 or GHRH, restoring estradiol raised pulsatile growth hormone release compared with estradiol depletion.
Peptide
GHRP-2
Outcome
IncreasePulsatile GH secretion, E2 repletion vs depletion
Study
n = 42
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
Submaximally stimulated pulsatile GH secretion was positively determined by PRE vs. POST age (P < 0.001), E(2) repletion vs. depletion (P = 0.001) and GHRP-2 vs. GHRH stimulation (P < 0.001), after adjustment for AVF and basal secretion.
2 context sentences(design, population, supporting numbers)
Summary · context
Community-dwelling healthy premenopausal (PRE, age 24 +/- 0.8 yr, n = 20) and postmenopausal (POST, age 63 +/- 1.8 yr, n = 22) women participated in the study.
Summary · context
Gonadal-axis down-regulation with leuprolide was followed by randomized addback of placebo or transdermal E(2) and separate-day iv bolus injections of a half-maximally stimulatory dose of GHRP-2 or GHRH (each 0.33 mug/kg).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1985831503
04HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome
In healthy pre- and postmenopausal women, E2 versus placebo elevated fasting mean GH concentrations.
In plain wordsIn healthy women, estradiol raised fasting growth hormone levels compared with placebo.
Peptide
GHRP-2
Outcome
IncreaseFasting mean GH concentration with E2
Study
n = 42
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
E(2) vs. placebo elevated fasting mean GH concentrations in both PRE and POST women (P = 0.006) but increased basal (nonpulsatile) GH secretion in PRE only (P = 0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
Community-dwelling healthy premenopausal (PRE, age 24 +/- 0.8 yr, n = 20) and postmenopausal (POST, age 63 +/- 1.8 yr, n = 22) women participated in the study.
Summary · context
Gonadal-axis down-regulation with leuprolide was followed by randomized addback of placebo or transdermal E(2) and separate-day iv bolus injections of a half-maximally stimulatory dose of GHRP-2 or GHRH (each 0.33 mug/kg).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1985831504
05HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome
In healthy premenopausal women only, E2 versus placebo increased basal (nonpulsatile) GH secretion.
In plain wordsIn healthy premenopausal women only, estradiol raised basal growth hormone release compared with placebo.
Peptide
GHRP-2
Outcome
IncreaseBasal (nonpulsatile) GH secretion with E2
Study
n = 42
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
E(2) vs. placebo elevated fasting mean GH concentrations in both PRE and POST women (P = 0.006) but increased basal (nonpulsatile) GH secretion in PRE only (P = 0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
Community-dwelling healthy premenopausal (PRE, age 24 +/- 0.8 yr, n = 20) and postmenopausal (POST, age 63 +/- 1.8 yr, n = 22) women participated in the study.
Summary · context
Gonadal-axis down-regulation with leuprolide was followed by randomized addback of placebo or transdermal E(2) and separate-day iv bolus injections of a half-maximally stimulatory dose of GHRP-2 or GHRH (each 0.33 mug/kg).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1985831505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:37 UTC
Study data updated · source update from Europe PMC
Version 2
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.